ADA26: Dexcom’s G7 CGM helps TD2 diabetics not on insulin manage glucose levels

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

Dexcom bolsters evidence for glucose sensors for Type 2 diabetes

New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...
Zacks Investment Research on MSN

Dexcom reports positive CONNECT data for non-insulin diabetes

DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...
Drug Delivery Business

Dexcom study highlights benefits of G7 CGM in non-insulin type 2 diabetes

Researchers shared findings today at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. San ...

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...

Clinical wins boost Dexcom growth story in type 2 diabetes

DexCom Inc. DXCM stock is trading higher on Monday after the diabetes management company reported positive results from its ...

Dexcom study finds G7 glucose monitor improves blood sugar control in type 2 diabetes patients

A new study presented at the American Diabetes Association found that Dexcom’s G7 continuous glucose monitor significantly ...
MassDevice

MyLife integrates MyLoop automated insulin pump with Dexcom G7

MyLife Diabetes Care, CamDiab and Dexcom today announced the integration of the G7 continuous glucose monitor (CGM) into the ...

Dexcom Warns Stolen G7 Glucose Sensors May Pose Infection, Reading Risks

Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks.
Medical Device and Diagnostic Industry (MD+DI)Opinion

Dexcom Learns a Lesson in Transparency

Customers have known for months that the Dexcom G7 continuous glucose monitoring sensor had problems. Now, the company is ...
Benzinga.com

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...